Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil EL&P Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Dr. Reddy's Laboratories Ltd ADR (NY: RDY ) 15.11 +0.02 (+0.13%) Official Closing Price Updated: 7:00 PM EST, Nov 8, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings Press Releases about Dr. Reddy's Laboratories Ltd ADR < Previous 1 2 3 Next > Dr. Reddy’s Q2 & H1FY25 Financial Results November 05, 2024 From Dr. Reddy’s Laboratories Ltd. Via Business Wire Dr. Reddy's Named by Science Magazine in Top 20 Global Pharma Employers List for Third Consecutive Year October 25, 2024 From Dr. Reddy’s Laboratories Ltd. Via Business Wire Dr. Reddy’s Launches Comprehensive Menopause Support Program and Training for Employees During Menopause Awareness Month October 14, 2024 From Dr. Reddy’s Laboratories Inc. Via Business Wire Market Alert: Dr. Reddy’s Labs Reports New Data for Aurigene CAR-T Phase 1, Gets Approvals for Phase 2 Trials Progression October 09, 2024 Via AB Newswire Aurigene Oncology Limited Announces Promising Results of Phase 1 Study for India’s First Trial for Novel Autologous CAR-T Cell Therapy for Multiple Myeloma October 08, 2024 From Aurigene Oncology Limited Via Business Wire Dr. Reddy’s signs voluntary licensing agreement with Gilead Sciences to manufacture and commercialise Lenacapavir in India and other countries October 02, 2024 From Dr. Reddy’s Laboratories Ltd. Via Business Wire Dr. Reddy’s Laboratories, Aurigene Pharmaceutical Services, and Kainomyx Announce Potential Partnership for Joint Development of Affordable Anti-Malarial Drug August 20, 2024 From Dr. Reddy’s Laboratories Ltd. Via Business Wire Dr. Reddy’s Receives Positive CHMP Opinion From European Medicines Agency for Its Proposed Rituximab Biosimilar July 29, 2024 From Dr. Reddy’s Laboratories Ltd. Via Business Wire Dr. Reddy’s Q1FY25 Financial Results July 27, 2024 From Dr. Reddy’s Laboratories Ltd. Via Business Wire Teva Pharmaceuticals Stock: Unlock Value in This Generic Drug Gem July 10, 2024 Drug prices continue to rise, driving up healthcare costs. Pharmaceutical companies usually hike drug prices at the beginning of each year. In January 2024 Via MarketBeat Aurigene Pharmaceutical Services Limited, a Global CRDMO, Announces the Opening of Its Biologics Facility Offering Process Development and Clinical Scale Manufacturing Capabilities June 03, 2024 From Aurigene Pharmaceutical Services Ltd. Via Business Wire Dr. Reddy’s to Acquire Nicotinell and Related Portfolio in Significant Step Towards Building Global Consumer Healthcare Business June 26, 2024 From Dr. Reddy’s Laboratories Ltd. Via Business Wire Dr. Reddy's Laboratories Announces the Appointment of Milan Kalawadia to CEO North America May 28, 2024 From Dr. Reddy's Laboratories Ltd. Via Business Wire Alvotech and Dr. Reddy’s Enter Into Collaboration for Commercialization of AVT03 (denosumab), a Biosimilar Candidate to Prolia® & Xgeva® in the U.S., Europe and UK May 21, 2024 From Dr. Reddy’s Laboratories Ltd. Via Business Wire Alvotech and Dr. Reddy’s enter into collaboration for commercialization of AVT03 (denosumab), a biosimilar candidate to Prolia® & Xgeva® in the U.S., Europe and UK May 21, 2024 From Alvotech Via GlobeNewswire Dr. Reddy’s Q4 & Full Year FY24 Financial Results May 07, 2024 From Dr. Reddy’s Laboratories Ltd. Via Business Wire Dr. Reddy's Laboratories Announces the Launch of Doxycycline Capsules, 40 mg* in the U.S. May 03, 2024 From Dr. Reddy's Laboratories Ltd. Via Business Wire Dr. Reddy's Laboratories launches Versavo® (bevacizumab) in the UK March 19, 2024 From Dr. Reddy’s Laboratories Ltd. Via Business Wire Dr. Reddy’s Q3 & 9M FY24 Financial Results January 31, 2024 From Dr. Reddy’s Laboratories Ltd. Via Business Wire Dr. Reddy's Announces the Acquisition of MenoLabs®, a Leading Women’s Health and Dietary Supplements Portfolio of Brands January 03, 2024 From Dr. Reddy's Laboratories Ltd. Via Business Wire Dr. Reddy’s becomes first Indian pharma company to debut on the Dow Jones Sustainability World Index December 14, 2023 From Dr. Reddy’s Laboratories Ltd. Via Business Wire Coya Therapeutics, Inc. and Dr. Reddy’s Laboratories Enter into an Exclusive Collaboration for Development and Commercialization of COYA 302, an Investigational Combination Therapy for Treatment of Amyotrophic Lateral Sclerosis (ALS) December 06, 2023 From Coya Therapeutics, Inc. Via Business Wire 2 overlooked stocks that crushed earnings but traded lower November 20, 2023 As the third quarter 2023 earnings season ends, it's worth looking back to see which stocks may have been overlooked or mispriced on their results Via MarketBeat Exposures Product Safety Dr. Reddy’s Q2 FY24 Financial Results October 27, 2023 From Dr. Reddy’s Laboratories Ltd. Via Business Wire Dr. Reddy's Laboratories Announces its Launch of Saxagliptin and Metformin Hydrochloride Extended-Release Tablets in the U.S. August 10, 2023 From Dr. Reddy's Laboratories Ltd. Via Business Wire Dr. Reddy’s Q1 FY24 Financial Results July 26, 2023 From Dr. Reddy’s Laboratories Ltd. Via Business Wire Dr. Reddy’s Proposed Rituximab Biosimilar Application Accepted for Review by USFDA, EMA and MHRA July 12, 2023 From Dr. Reddy’s Laboratories Ltd. Via Business Wire Drugmaker GSK: Becoming a Healthier Value Stock June 27, 2023 Up more than 25% in the last nine months, U.K. pharmaceutical company GSK PLC is slowly regaining favor with investors after the GSK lawsuit. Via MarketBeat Topics Lawsuit Exposures Financial Legal Dr. Reddy’s Successfully Completes Phase I Study (IV Route) of DRL_TC, a Proposed Biosimilar of Tocilizumab June 05, 2023 From Dr. Reddy’s Laboratories Ltd. Via Business Wire Dr. Reddy’s Q4 & FY23 Financial Results May 10, 2023 From Dr. Reddy’s Laboratories Ltd. Via Business Wire < Previous 1 2 3 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.
